Ladies and gentlemen,

Please find below the new Absorber Newsletter regarding the Early Morning Symposium during the TTS Congress in Vancouver, August 16, 2010.

Thank you for your attention and best regards

Julia Hirtle
Sales and Marketing Manager Distribution

AbSorber hosted an Early Morning Symposium during the TTS Congress in Vancouver, August 16

Improving outcomes in kidney transplantation: Non-HLA antibodies and Enhanced Clinical Risk Assessment

HLA-specific antibodies present before kidney transplantation or induced after transplantation have been associated with hyperacute and acute vascular rejection episodes, graft loss, and poor long-term graft survival. There is increasing evidence that the presence of non-HLA antibodies reactive with donor endothelial cells contribute to short and long term complications in renal transplant recipients. During the symposium enhanced risk assessment focusing on the detection of non-HLA antibodies was discussed.

Program

AbSorber is excited about the very positive interest that XM-ONE has received in the transplant community around the world. AbSorber's symposium, at this important congress, gave the participants an even better understanding of the clinical role of XM-ONE in organ transplantation, according to Anders Karlsson, CEO of AbSorber.

XM-ONE is a standardized, cell based, crossmatch test for clinical use. The use of XM-ONE allows you to identify patients at risk for developing acute rejections and post-transplant complications. XM-ONE provides additional information compared to the currently used lymphocyte crossmatch tests and therefore improves the basis for risk assessment prior to transplantation.